The results of a randomized controlled trial published Monday showed oral ketamine tablets were safe and effective for patients with treatment-resistant depression — the latest attempt by researchers to rigorously evaluate psychedelic drugs’ role in treating conditions like depression, anxiety, and post-traumatic stress disorder.
In the Phase 2 trial, the findings of which were detailed in Nature Medicine, patients who took extended release ketamine tablets at a 180-milligram dosage twice weekly showed a “statistically significant and clinically meaningful improvement in depressive symptoms” compared to a placebo. Other dosages saw less of an impact.
advertisement
The study, sponsored by New Zealand-based Douglas Pharmaceuticals, is a step toward gathering evidence that could eventually be presented to federal regulators in search of approval for depression treatment, though researchers would still need to complete much larger studies first.
STAT+ Exclusive Story
Already have an account? Log in
Get unlimited access to award-winning journalism and exclusive events.